TOVX · Theriva Biologics, Inc. · Financials
$0.25
+0.00 (+2.02%)
At close · Sep 11
Going-concern doubt
— flagged Aug 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Management has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that these financial statements are issued. The Company's ability to continue as a going concern is dependent upon the Company's ability to raise additional debt and equity capital or secure a potential license or strategic relationship that can help fund its clinical development activities. There can be no assurance that such capital will be available in sufficient amounts or on terms acceptable to the Company. These factors raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 11, 2026
Market Cap
$11.36M
Shares
45.89M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$0
-100%
FY2011
Net Income
-$23.74M
+7.5%
FY2025
Diluted EPS
-$2.08
+89.1%
FY2025
Operating Cash Flow
-$16.67M
+1.6%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $0 | $2.61M | |
| $5.31M | $8.6M | $12.03M | $14.31M | $11.72M | $7.8M | $5.13M | $11.08M | $11.84M | $18.78M | $29.11M | $32.91M | $14.49M | $6.51M | $12.29M | $3.34M | $1.58M | |
| $6.92M | $15.45M | $7.4M | $7.12M | $9.86M | $6.47M | $5.03M | $4.58M | $5.73M | $7.47M | $10.14M | $8.07M | $6.01M | $5.83M | $5.01M | $2.59M | $2.12M | |
| $103K | $108K | $137K | $135K | $85K | $87K | $201K | $240K | $272K | $245K | $157K | $72K | $20K | $43K | — | — | — | |
| $12.22M | $24.05M | $26.35M | $21.43M | $21.58M | $14.27M | $10.16M | $15.66M | $17.57M | $26.25M | $39.25M | $40.98M | $20.5M | $12.34M | $17.3M | $5.93M | $3.7M | |
| -$11.92M | -$24.05M | -$26.35M | -$21.43M | -$21.58M | -$14.27M | -$10.16M | -$15.66M | -$17.57M | -$26.25M | -$39.25M | -$40.98M | -$20.5M | -$12.34M | -$17.3M | — | — | |
| -$11.82M | -$23.94M | -$26.21M | -$21.3M | -$21.5M | -$14.19M | -$9.96M | -$15.42M | -$17.3M | -$26.01M | -$39.1M | -$40.91M | -$20.48M | -$12.3M | — | — | — | |
| $298K | $287K | $697K | $1.44M | $512K | $6000 | $44K | $283K | $67K | $21K | $37K | $6000 | $3000 | $33K | $33K | $14K | $0 | |
| $306K | $312K | $693K | $1.44M | $471K | $6000 | $44K | $283K | $4.15M | $10.76M | $11.45M | -$3.81M | $718K | $21K | $15K | -$1.7M | -$112K | |
| -$11.62M | -$23.74M | -$25.65M | -$19.99M | -$21.11M | -$14.27M | — | — | — | — | — | — | — | -$12.34M | -$17.3M | -$5.93M | -$1.08M | |
| — | — | $0 | -$1.64M | -$1.43M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | |
| -$11.62M | -$23.74M | -$25.65M | -$18.35M | -$19.69M | -$14.27M | -$10.04M | -$15.3M | -$13.37M | -$15.17M | -$27.26M | -$43.74M | -$19.78M | -$12.32M | -$17.07M | -$8.15M | -$1.71M | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -65.46% | |
| — | — | — | — | $0 | -$1000 | -$73K | -$77K | -$54K | -$318K | -$548K | -$1.05M | $0 | -$1000 | $0 | — | — | |
| -$13.13M | -$25.25M | -$25.65M | -$18.35M | -$20.03M | -$23.19M | -$12.56M | -$16.08M | -$25.29M | -$22.14M | -$27.26M | -$43.74M | — | — | — | — | — | |
| — | — | — | — | -$20.36M | -$14.27M | — | — | — | — | — | — | — | — | — | — | — | |
| USD/shares | $1.28 | -$2.08 | -$19.03 | -$28.48 | -$32.75 | -$47.50 | -$165.00 | — | — | — | — | — | — | — | — | — | — |
| USD/shares | $1.28 | -$2.08 | -$19.03 | -$28.48 | -$32.75 | -$47.50 | -$165.00 | — | — | — | — | — | — | — | — | — | — |
| shares | — | 12.14M | 1.35M | 644.28K | 613.09K | 487.5K | 76.05K | 65.75K | 24.93K | 14.21K | 377.16K | 322.82K | 247.78K | 182.67K | 139.59K | 110.84K | — |
| shares | — | 12.14M | 1.35M | 644.28K | 613.09K | 487.5K | 76.05K | 65.75K | 24.93K | 14.21K | 377.16K | 322.82K | 247.78K | 182.67K | 139.59K | 110.84K | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 1.92×
EV/EBIT
—
P/E (TTM)
—
Peer median 3.06×
Peer medians compare against the 214 similar-size Biotechnology companies (of 536 listed).